Aptevo Therapeutics 미래 성장

Future 기준 확인 3/6

Aptevo Therapeutics은 연간 수입과 매출이 각각 66.5%와 78.9% 증가할 것으로 예상되고 EPS는 연간 69.4%만큼 증가할 것으로 예상됩니다.

주요 정보

66.5%

수익 성장률

69.4%

EPS 성장률

Biotechs 수익 성장	27.5%
매출 성장률	78.9%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	07 Nov 2024

최근 미래 성장 업데이트

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

수익 및 매출 성장 예측

NasdaqCM:APVO - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	8	-14	N/A	N/A	1
12/31/2025	N/A	-21	N/A	N/A	1
12/31/2024	N/A	-23	N/A	N/A	1
9/30/2024	N/A	-24	-23	-23	N/A
6/30/2024	N/A	-25	-24	-24	N/A
3/31/2024	N/A	-27	-23	-23	N/A
12/31/2023	N/A	-19	-12	-12	N/A
9/30/2023	N/A	-18	-12	-12	N/A
6/30/2023	N/A	-19	-13	-13	N/A
3/31/2023	N/A	17	-11	-11	N/A
12/31/2022	3	7	-21	-21	N/A
9/30/2022	7	6	-19	-19	N/A
6/30/2022	10	6	-17	-17	N/A
3/31/2022	13	-30	-20	-19	N/A
12/31/2021	12	-29	-22	-22	N/A
9/30/2021	11	-30	-25	-24	N/A
6/30/2021	9	-30	-27	-26	N/A
3/31/2021	7	-29	-26	-26	N/A
12/31/2020	4	-31	-29	-29	N/A
9/30/2020	2	-33	-28	-28	N/A
6/30/2020	0	-37	-28	-28	N/A
3/31/2020	N/A	-41	-40	-40	N/A
12/31/2019	N/A	-43	-43	-42	N/A
9/30/2019	6	-48	-45	-45	N/A
6/30/2019	12	-49	-49	-48	N/A
3/31/2019	19	-52	-49	-48	N/A
12/31/2018	23	-54	-52	-51	N/A
9/30/2018	20	-49	-61	-60	N/A
6/30/2018	20	-34	N/A	-50	N/A
3/31/2018	17	-35	N/A	-47	N/A
12/31/2017	15	-33	N/A	-42	N/A
9/30/2017	15	-39	N/A	-33	N/A
6/30/2017	11	-115	N/A	-31	N/A
3/31/2017	4	-119	N/A	-35	N/A
12/31/2016	10	-120	N/A	-37	N/A
9/30/2016	15	-122	N/A	-38	N/A
6/30/2016	19	-61	N/A	-47	N/A
3/31/2016	30	-61	N/A	-47	N/A
12/31/2015	34	-59	N/A	-49	N/A
12/31/2014	46	-51	N/A	-47	N/A
12/31/2013	0	-53	N/A	-51	N/A

애널리스트 미래 성장 예측

수입 대 저축률: APVO 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: APVO (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: APVO 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: APVO 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: APVO 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: APVO 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Aptevo Therapeutics 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 49% to US$671

Price target decreased by 33% to US$12.00

Consensus forecasts updated

Price target decreased to US$18.00

Consensus forecasts updated

Consensus revenue estimates fall by 15%

Recent updates

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial Initiated

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견